Methods and Biomarkers for Diagnosing and Monitoring Psychotic Disorders

• US 20090176257A1
• Filed: 10/18/2006
• Published: 07/09/2009
• Est. Priority Date: 10/18/2005
• Status: Abandoned Application

• Current Assignee: Psynova Neurotech Ltd. (Myriad Genetics)
• Original Assignee: Psynova Neurotech Ltd. (Myriad Genetics)
• Inventors: -J Huang, Jeffery T., Tsang, Tsz, Bahn, Sabine
• Application Number:
  US12/090,530
• Publication Number:
  US 20090176257A1
• Time in Patent Office: Days
• US Class Current: 435/7.920
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: G01R 33/465 applied to biological material, e.g. in vitro testing
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

The invention relates to methods of diagnosing or monitoring a psychotic disorder in a subject comprising providing a test biological sample from the subject, performing spectral analysis on said test biological sample to provide one or more spectra, and, comparing the one or more spectra with one or more control spectra. The invention also relates to methods for diagnosing or monitoring psychotic disorders such as schizophrenic or bipolar disorders, comprising measuring the level of one or more biomarkers present in a biological sample taken from a test subject, said biomarkers being selected from the group consisting of transthyretin, ApoA1: VLDL, LDL and aromatic species such as plasma proteins. The invention also relates to sensors, biosensors, multi-analyte panels, arrays, assays and kits for performing methods of the invention.

Claims

1-75. -75. (canceled)

76. A method selected from the group consisting of:

i) diagnosing or monitoring a psychotic disorder, or predisposition thereto, and

ii) monitoring efficacy of a therapy in a subject having, suspected of having, or suspected of being predisposed to, a psychotic disorder,

wherein said method comprises measuring the level of one or more biomarkers present in a sample taken from a subject, said biomarkers being selected from a transthyretin peptide comprising SEQ ID NO;

1 or a fragment thereof, an ApoA1 peptide comprising SEQ ID NO;

2 or a fragment thereof, VLDL, LDL and aromatic species.

78. The method according to claim 76, comprising comparing the levels of the one or more biomarkers in a sample taken from the subject with the level present in one or more samples taken from the subject prior to commencement of a therapy, and/or one or more samples taken from the subject at an earlier stage of a therapy.

79. The method according to claim 76, comprising detecting a change in the amount of the one or more biomarkers in samples taken on two or more occasions.

80. The method according to claim 76, comprising comparing the amount of the one or more biomarkers present in a sample with the level in one or more controls.

81. The method according to claim 80, wherein the controls are a normal control and/or a psychotic disorder control.

82. The method according to claim 76, wherein the level of one or more biomarkers is detected by one or more methods selected from NMR, SELDI (-TOF), MALDI (-TOF), a 1-D gel-based analysis, a 2-D gel-based analysis, mass spectrometry (MS), a LC-MS-based technique, direct or indirect, coupled or uncoupled enzymatic methods, electrochemical, spectrophotometric, fluorimetric, luminometric, spectrometric, polarimetric and chromatographic techniques, and immunological methods.

83. The method according to claim 76, wherein the biomarker is VLDL and/or LDL and the level thereof is detected by one or more methods selected from a liquid-phase chemical method, a physical method for separation of lipoproteins and an enzymatic assay.

84. The method according to claim 76, wherein the level of one or more biomarkers is detected using a sensor or biosensor comprising one or more enzymes, binding, receptor or transporter proteins, antibody, synthetic receptors or other selective binding molecules for direct or indirect detection of the biomarkers, said detection being coupled to an electrical, optical, acoustic, magnetic or thermal transducer.

85. The method according to claim 76, wherein the sample is selected from whole blood, blood serum, blood plasma, CSF, urine, saliva, or other bodily fluid, or breath, condensed breath or an extract or purification therefrom, or dilution thereof.

86. The method according to claim 76, wherein the subject is drug-naï

ve.

87. The method according to claim 76, wherein the psychotic disorder is a schizophrenic disorder.

88. The method according to claim 87, wherein the psychotic disorder is a bipolar disorder.

89. The method according to claim 76, further comprising a clinical or self-assessment of the subject.

77. A method of identifying an anti-psychotic substance, comprising measuring the level of one or more biomarkers present in a sample taken from a subject, said biomarkers being selected from a transthyretin peptide comprising SEQ ID NO:

1 or a fragment thereof an ApoA1 peptide comprising SEQ ID NO;

2 or a fragment thereof, VLDL, LDL and aromatic species.

90. The method according to claim 77, comprising comparing the levels of the one or more biomarkers in a sample taken from the subject with the level present in one or more samples taken from the subject prior to commencement of a therapy, and/or one or more samples taken from the subject at an earlier stage of a therapy.

91. The method according to claim 77, comprising detecting a change in the amount of the one or more biomarkers in samples taken on two or more occasions.

92. The method according to claim 77, comprising comparing the amount of the one or more biomarkers present in a sample with the level in one or more controls.

93. The method according to claim 92, wherein the controls are a normal control and/or a psychotic disorder control.

94. The method according to claim 77, wherein the level of one or more biomarkers is detected by one or more methods selected from NMR, SELDI (-TOF), MALDI (-TOF), a 1-D gel-based analysis, a 2-D gel-based analysis, mass spectrometry (MS), a LC-MS-based technique, direct or indirect, coupled or uncoupled enzymatic methods, electrochemical, spectrophotometric, fluorimetric, luminometric, spectrometric, polarimetric and chromatographic techniques, and immunological methods.

95. The method according to claim 77, wherein the biomarker is VLDL and/or LDL and the level thereof is detected by one or more methods selected from a liquid-phase chemical method, a physical method for separation of lipoproteins and an enzymatic assay.

96. The method according to claim 77, wherein the level of one or more biomarkers is detected using a sensor or biosensor comprising one or more enzymes, binding, receptor or transporter proteins, antibody, synthetic receptors or other selective binding molecules for direct or indirect detection of the biomarkers, said detection being coupled to an electrical, optical, acoustic, magnetic or thermal transducer.

97. The method according to claim 77, wherein the sample is selected from whole blood, blood serum, blood plasma, CSF, urine, saliva, or other bodily fluid, or breath, condensed breath or an extract or purification therefrom, or dilution thereof.

98. The method according to claim 77, wherein the subject is drug-naï

ve.

99. The method according to claim 77, wherein the psychotic disorder is a schizophrenic disorder.

100. The method according to claim 99, wherein the psychotic disorder is a bipolar disorder.

101. The method according to claim 77, further comprising a clinical or self-assessment of the subject.